Tirazone
(tirapazamine)Phase 3Small molecule
SanofiTirapazamine is used as a cancer treatment, particularly for head and neck cancers and cervical cancer, often combined with radiation therapy to make cancer cells more vulnerable to treatment.[1] Tirazone is currently being investigated across 7 indications[3], with its most advanced program in Phase 3.[1]
Tirazone is one of 257 small molecule programs targeting Alzheimer disease. It is currently in Phase 3.
7
Indications
19
Total Trials
2
Active Trials
256
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Tirazone
SanofiPhase 3
Yervoy
Bristol-Myers SquibbPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
PORTRAZZA
Eli LillyPreclinical
Imjudo
AstraZenecaPreclinical
Vizimpro
PfizerPreclinical
Gilotrif
Boehringer IngelheimPreclinical
Ofev
Boehringer IngelheimPreclinical
Immunotherapy
Bristol-Myers SquibbPreclinical
Remeron
OOrganon and Co
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Liver Cancer3 trials
Non-Small Cell Lung Cancer3 trials
Cervical Cancer3 trials
Small Cell Lung Cancer2 trials
7 more indications
Head and Neck Cancer1 trial
Rhabdomyosarcoma1 trial
Primary Peritoneal Cancer1 trial
Advanced Malignant Solid Tumors1 trial
Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors
Completed·—·Phase 1·NCT00005078·44 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for tirapazamine. EMBL-EBI & Wellcome Sanger Institute.
- [4]